Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery.

We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our Core Values drive the way we work together:

Dare to Cure
Break Boundaries
Beyond Yourself
Prepare & Execute Relentlessly

Join us in creating the future of genetic medicine.

GENERAL SUMMARY

The Executive Medical Director will report to the CMO, with a dotted-line relationship to the SVP of Research & Early-Stage Product Development, and will be responsible for the design, execution, and analysis of clinical trials in the ophthalmology therapeutic area

MAJOR DUTIES & RESPONSIBILITIES

Clinical Development Leadership
Serve as the clinical lead for Phase 1 retina clinical trials, including study design, protocol development, dose escalation strategy, and safety oversight
Maintain accountability for study execution, data interpretation, and clinical readouts, including early signal detection and go/no-go recommendations
Serve as medical monitor for assigned studies, ensuring subject safety and data integrity
Lead cross-functional study teams (clinical operations, clinical science, biometrics, regulatory, safety, CMC, etc.) to ensure high-quality and timely trial delivery
Provides clinical leadership to multidisciplinary study execution teams drawn from clinical operations, clinical science, biometrics, regulatory affairs, CMC, pharm/tox, drug safety, commercial, and alliance partners
Has lead accountability on the study teams for delivery of study protocols, study conduct, and study readouts
Biomarker & Translational Strategy
Lead development and implementation of biomarker strategies for GA and broader retina programs
Collaborate with research and translational teams to identify, validate, and integrate imaging, molecular, and functional biomarkers into early-phase trials
Ensure biomarkers are aligned with mechanism of action, dose selection, and clinical endpoints to support decision-making and regulatory strategy
Regulatory & Clinical Documentation
Serve as the primary clinical author of development plans, protocols, IBs, INDs, CSRs, and regulatory responses
Lead clinical contributions to IND submissions and early regulatory interactions, including Health Authority meetings for Phase 1 programs
Ensure accuracy, scientific rigor, and regulatory compliance of all clinical documents